Kubheka Thandeka I, Naidoo Kewreshini, Reddy Kavidha, Ndung'u Thumbi, Mkhwanazi Nompumelelo P
HIV Pathogenesis Program, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, College of Health Sciences University of KwaZulu-Natal, Durban, South Africa.
Africa Health Research Institute, Durban, South Africa.
Front Immunol. 2025 Jun 18;16:1564960. doi: 10.3389/fimmu.2025.1564960. eCollection 2025.
The HIV-1 Tat protein is essential for virus replication and spread and is therefore a potential target for anti-HIV therapy. Anti-Tat antibodies have been shown to slow HIV disease progression and improve antiretroviral therapy (ART) efficacy. Long-term ART results in partial reconstitution of the immune system in people living with HIV-1 (PLWH) who start treatment in the chronic phase of infection, but the impact of ART initiation in the acute phase of infection is less studied. In this study, we investigate the effect of initiating ART in acute phase infection on the production of anti-Tat antibodies and on T-cell activation.
Anti-Tat IgA, IgG, and IgM titres were evaluated longitudinally by enzyme-linked immunosorbent assay in plasma samples collected from 34 women who started ART immediately following the detection of acute HIV-1 infection. Total HIV-1 DNA measurements were performed by droplet digital PCR from total peripheral blood mononuclear cells at 1-year post ART initiation. T-cell activation was assessed longitudinally by analysis of the expression of HLA-DR and CD38 on CD4+ and CD8+ T-cells using flow cytometry. We also explored the association between anti-Tat antibody titres and CD4+ T-cell counts.
The data showed that anti-Tat IgG and IgM titres had decreased significantly after 12 months of treatment (p=0.0001) with no correlation between anti-Tat IgA, IgG or IgM and CD4+ T-cell counts (r= -0.09 to 0.2, p>0.05). There was no correlation between anti-Tat antibody levels and total HIV-1 DNA levels at ART initiation (r= 0.2143, p= 0. 6191) or after 12 months post-ART (r= -0. 2857, p= 0, 5008). There was a significant decrease in CD8+ T-cell activation between the baseline (day 1 on ART) and 12 months post-ART (p=0.0129).
These findings suggest early initiation of ART reduces the production of anti-Tat antibodies and reduces CD8+ T-cell activation. Further studies on the impact of early ART on antiviral immune responses are needed and may shed light on mechanisms of optimal immune reconstitution and reservoir control in PLWH.
HIV-1反式激活蛋白(Tat蛋白)对于病毒复制和传播至关重要,因此是抗HIV治疗的潜在靶点。抗Tat抗体已被证明可减缓HIV疾病进展并提高抗逆转录病毒疗法(ART)的疗效。长期ART可使在感染慢性期开始治疗的HIV-1感染者(PLWH)的免疫系统得到部分重建,但在感染急性期开始ART的影响研究较少。在本研究中,我们调查了在急性期感染时开始ART对抗Tat抗体产生及T细胞活化的影响。
通过酶联免疫吸附测定法纵向评估从34名在检测到急性HIV-1感染后立即开始ART的女性血浆样本中的抗Tat IgA、IgG和IgM滴度。在ART开始后1年,通过液滴数字PCR对全外周血单个核细胞进行总HIV-1 DNA测量。使用流式细胞术通过分析CD4+和CD8+ T细胞上HLA-DR和CD38的表达纵向评估T细胞活化。我们还探讨了抗Tat抗体滴度与CD4+ T细胞计数之间的关联。
数据显示,治疗12个月后抗Tat IgG和IgM滴度显著下降(p = 0.0001),抗Tat IgA、IgG或IgM与CD4+ T细胞计数之间无相关性(r = -0.09至0.2,p>0.05)。在ART开始时(r = 0.2143,p = 0.6191)或ART后12个月(r = -0.2857,p = 0.5008),抗Tat抗体水平与总HIV-1 DNA水平之间均无相关性。在基线(ART第1天)和ART后12个月之间,CD8+ T细胞活化显著降低(p = 0.0129)。
这些发现表明早期开始ART可减少抗Tat抗体的产生并降低CD8+ T细胞活化。需要进一步研究早期ART对抗病毒免疫反应的影响,这可能有助于阐明PLWH中最佳免疫重建和病毒库控制的机制。